After months of stop-start negotiations  Johnson & Johnson walked away from discussions in mid-December, only for the companies to restart exclusive talks about a deal a few days later  the deal would add Actelion’s treatments for pulmonary arterial hypertension, or high blood pressure in the lungs, to the American giant’s stable.